Form 4: Lyell Immunopharma Director Mark Bachleda Granted 13,000 Stock Options

Lyell Immunopharma, Inc. Director Mark Bachleda was granted 13,000 stock options with an exercise price of $12.47, vesting monthly over three years.

Summary

• Mark Bachleda, a Director of Lyell Immunopharma, Inc. (LYEL), was granted 13,000 stock options.
• The options have an exercise price of $12.47 per share.
• The grant date for these options was June 9, 2025.
• The options will vest monthly over a 36-month period (1/36th per month), contingent on Mr. Bachleda's continued service as a director.
• The expiration date for these options is June 8, 2035.
• Following this transaction, Mr. Bachleda beneficially owns 13,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of options is a positive signal of continued director involvement and alignment with shareholder interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a director serves as an incentive, aligning the director's financial interests with the company's long-term stock performance.
• The vesting schedule encourages long-term commitment and retention of key board members.

Future Outlook

This filing reports a standard equity compensation grant to a director, which is intended to incentivize long-term performance. It does not provide broader forward-looking statements regarding the company's operational or financial outlook.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to attract and retain executive talent and align their interests with shareholder value, particularly given the long development cycles and high-risk nature of the sector.

Comparison to Industry Standards

• Equity compensation, including stock option grants, is a standard practice across publicly traded companies, especially in high-growth sectors like biotechnology.
• The specific terms (exercise price, vesting schedule) are typically determined by the company's compensation committee based on market benchmarks for director compensation, though no specific comparable companies or projects are mentioned in this filing.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also aligns director's interests with share price appreciation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The options will vest monthly over the next 36 months, subject to the director's continued service.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, LYEL, Form 4, SEC filing, insider transaction, stock options, director compensation, equity grant, beneficial ownership